Parmax Pharma Share Price | Parmax Pharma Stock Screener
PARMAX
Pharmaceuticals
Share Price BSE
₹39.96
▲
2.06 (5.44%)
As of May 27, 2026, the Parmax Pharma share price (BSE: PARMAX) is ₹39.96, up 5.44% from the previous close, with shares trading between ₹38.70 and ₹43.00, and a 52-week range of ₹25.22–₹45.66.
Check Parmax Pharma yearly highs lows for the annual price range and momentum.
Use the Parmax Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Parmax Pharma Market Cap
₹14.14 Cr.
PARMAX P/E Ratio (TTM)
-2.71
Parmax Pharma P/B Ratio
-2.48
EPS (TTM)
₹-5.60
Dividend Yield
-
Debt to Equity
-
PARMAX 52 Week High
₹45.66
Parmax Pharma 52 Week Low
₹25.22
Operating Margin
-29.00%
Profit Margin
-35.71%
PARMAX Revenue (TTM)
₹14.00
EBITDA
₹-4.00
Net Income
₹-5.00
Total Assets
₹19.00
Total Equity
₹-2.00
Parmax Pharma Share Price Chart
Screen Parmax Pharma share price with an interactive chart. Analyse PARMAX price trends and volatility across different timeframes.
Parmax Pharma Company Profile - Fundamental Screener
Screen Parmax Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for PARMAX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE240T01014
Parmax Pharma Balance Sheet Screener
Screen PARMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 19 | 15 | 18 | 18 | 23 | 21 | 20 | 17 | 8 | 5 |
| Current Assets | 10 | 6 | 8 | 7 | 10 | 9 | 9 | 9 | 4 | 2 |
| Fixed Assets | 8 | 9 | 10 | 10 | 11 | 10 | 5 | 6 | 3 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 8 | 6 | 5 | 5 | 6 | 5 | 5 | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | -2 | 0 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -6 | -4 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
Parmax Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Parmax Pharma income statement and profit fundamentals.
Analyze PARMAX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Parmax Pharma share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 28 | 11 | 16 | 18 | 26 | 21 | 12 | 12 | 0 | 0 |
| Expenses | 17 | 28 | 14 | 13 | 16 | 23 | 19 | 11 | 11 | 0 | 0 |
| EBITDA | -4 | 0 | -3 | 2 | 3 | 4 | 2 | 1 | 1 | 0 | 0 |
| Operating Profit % | -29.00% | 1.00% | -31.00% | 15.00% | 14.00% | 13.00% | 8.00% | 9.00% | 9.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -5 | -2 | -6 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -5 | -2 | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | -13.60 | -5.60 | -34.56 | -0.28 | 0.38 | 2.02 | 1.15 | 0.21 | 0.00 | -0.02 | -0.01 |
Parmax Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PARMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 0 | 0 | 1 | 4 | 3 | 1 | 4 | -1 | 0 |
| Investing Activities | -1 | -2 | -1 | -2 | -3 | -2 | -3 | -4 | 0 | 0 |
| Financing Activities | 1 | 1 | 0 | -1 | 0 | 0 | 3 | 1 | 1 | 0 |
| Net Cash Flow | 0 | 0 | -1 | -2 | 1 | 0 | 1 | 1 | 0 | 0 |
Parmax Pharma Shareholding Pattern Screener
See Parmax Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Parmax Pharma promoter holding and ownership changes for PARMAX on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 63.10% | 63.08% | 63.09% | 63.10% | 63.10% | 63.12% | 62.90% | 65.78% |
| Other Holding | 6.09% | 6.12% | 6.11% | 6.10% | 6.10% | 6.08% | 6.29% | 3.42% |
| Shareholder Count | 2,388 | 2,393 | 2,399 | 2,377 | 2,356 | 2,334 | 2,246 | 2,185 |
Parmax Pharma Share Dividend Screener - Share Yield Analysis
Check Parmax Pharma dividend history with payout and yield data.
View Parmax Pharma dividend details including ex-dates and amounts for PARMAX stock.
Parmax Pharma Stock Index Membership
See which indices include Parmax Pharma stock.
Check PARMAX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Parmax Pharma Market Events Screener - Corporate Actions
Get Parmax Pharma corporate actions including splits, bonuses, and buybacks.
Check Parmax Pharma stock events that may affect PARMAX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.64% | ||
| Annual General Meeting | NA | 11.04% | ||
| 2026-05-27 | 2026-05-27 | Extraordinary General Meeting | NA | 22.29% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.72% |
| 2025-11-17 | 2025-11-17 | Quarterly Result Announcement | NA | -1.84% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 2.12% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.09% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.75% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.73% |
Parmax Pharma Competitors Screener - Peer Comparison
Screen PARMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,422 | 40.42 | 58,220 | 6.38% | 11,565 | 54.03 |
| Divis Laboratories | 178,395 | 73.73 | 10,560 | 8.73% | 2,520 | 57.30 |
| Torrent Pharmaceuticals | 150,293 | 66.80 | 13,753 | 19.18% | 2,028 | 66.36 |
| Cipla | 114,398 | 29.26 | 27,712 | -2.46% | 3,783 | 64.19 |
| Dr Reddys Laboratories | 111,049 | 26.24 | 33,593 | -0.44% | 3,998 | 57.44 |
| Zydus Life Science | 108,708 | 20.40 | 26,720 | 13.65% | 5,242 | 73.90 |
| Lupin | 103,401 | 19.46 | 27,488 | 19.98% | 5,345 | 48.15 |
| Mankind Pharma | 99,775 | 52.84 | 14,278 | 12.03% | 1,750 | 59.66 |
| Aurobindo Pharma | 84,350 | 24.29 | 33,385 | 3.21% | 3,376 | 51.11 |
| Laurus Labs | 74,079 | 81.46 | 6,813 | 21.03% | 884 | 78.36 |
Parmax Pharma Company Announcements - News Screener
Screen PARMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-04 | Extra Ordinary General Meeting Scheduled To Be Held On May 27 2026 | - |
| 2026-05-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-17 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-03-25 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-02-14 | Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2025 | - |
| 2026-02-14 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-02-09 | Board Meeting Intimation for Consider And Approve Unaudited Financial Results For Quarter And Nine Months Ended On December 31 2025 | - |
| 2026-01-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Closure of Trading Window | - |
| 2025-11-17 | Results-Delay in Financial Results | - |
| 2025-11-17 | Board Meeting Outcome for The Board Meeting Was Initially Rescheduled On November 15 2025 And Thenafter On Today I.E. November 17 2025 Hence Board Has Approved The Unaudited Financial Statements For Quarter And Half Year Ended On September 30 2025 | - |
| 2025-11-15 | Board Meeting Intimation for Reschedule Of Board Meeting Supposed To Be Held On November 14 2025 | - |
| 2025-11-08 | Board Meeting Intimation for For Approval Of Unaudited Financial Results For Quarter Ended September 30 2025 | - |
| 2025-10-29 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-10-01 | Closure of Trading Window | - |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-09-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |